Aktien Sensor

Bristol-Myers Squibb’s stock price has plummeted 24% in the last month, with investors concerned about the looming patent cliff and the company’s ability to recover from its current slump.

Bristol-Myers Squibb’s stock price has stabilized, driven by recent advancements in its treatments, including the updated label for CAMZYOS and promising results for FYARRO in rare cancer treatment.

Bristol-Myers Squibb’s stock performance is volatile, with some analysts seeing potential for long-term growth, while others warn of impending collapse due to financial struggles and government policy concerns.

Bristol-Myers Squibb’s Breyanzi has shown promising efficacy and safety in a Phase 2 trial for treating relapsed or refractory indolent B-cell Non-Hodgkin Lymphoma.